Pharmacokinetic Study of Extended Infusion Meropenem in Adult Cystic Fibrosis Patients

NCT ID: NCT01158937

Last Updated: 2015-05-21

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 2 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-05-31
• Study Completion Date: 2014-01-31

Brief Summary

Meropenem is an intravenous antibiotic commonly used to treat acute exacerbation of respiratory infections in cystic fibrosis. The research study aims to determine if a different method of infusing the drug over 3 hours or longer, instead of the traditional half-hour will improve target attainment of drug concentrations and bactericidal activity. A secondary aim is to assess if the pharmacokinetics of meropenem is different during active infection compared to non-infective stage. Twelve patients admitted with acute respiratory infection and who requires meropenem will be enrolled into the study. Meropenem blood concentrations collected over 8 hours will be measured after half-hour and 3-hour infusions on different days. A pharmacokinetic modelling and Monte Carlo simulation program will use the data to assess and predict the optimal method of dosing. When patients return for a follow-up clinic visit, a single dose of meropenem will be administered and blood concentrations will be measured to determine the pharmacokinetics during non-infective stage.

Detailed Description

Meropenem plays a crucial role in the treatment of pulmonary exacerbations in cystic fibrosis patients, because it has activity against both P. aeruginosa and B. cepacia, two of the most problematic pathogens that are encountered in this disease. These organisms cause chronic endobronchitis with frequent exacerbations which lead to significant morbidity and premature mortality. Treatment options for pulmonary exacerbations are limited due to the high rates of resistance with currently available antibiotics and lack of development of new effective antibiotics. Therefore optimization of the dosing of meropenem, by use of extended infusion strategy, is one method to allow us to maximize the efficacy of this drug. Meropenem is a beta-lactam type antibiotic with time-dependent bactericidal activity and hence it is suitable for extended infusion dosing. The key rationale for extended infusion of beta-lactam antibiotics is to allow for optimization of pharmacodynamic target attainment of time above the minimal inhibitory concentrations (T>MIC) to maximize bactericidal killing and optimize clinical outcomes. The use of this infusion strategy has been studied in non-cystic fibrosis patients treated primarily with piperacillin-tazobactam or meropenem for P. aeruginosa infections. The application of this strategy in cystic fibrosis patients has not been well studied, and there is no data for the treatment of B. cepacia infections. Also the pharmacokinetic characteristics of meropenem in adult cystic fibrosis patients with pulmonary exacerbation have not been previously studied. It is unclear whether or not the pharmacokinetic profile of meropenem in patients without exacerbation can be accurately extrapolated to those patients with exacerbation. The first phase of this study will, therefore, describe the pharmacokinetic profile of meropenem and the distribution of MICs for P. aeruginosa and B. cepacia in a population of adult cystic fibrosis patients with pulmonary exacerbation. The data will be used to determine an optimal extended infusion dosing strategy specifically for our patients with cystic fibrosis. The second phase of our study will provide additional data on the pharmacokinetics of meropenem in patients without active infection.

Significance of study:

This study will provide new information regarding the pharmacokinetics of meropenem in a population of cystic fibrosis patients with pulmonary exacerbation. This will allow us to apply Monte Carlo simulation to the data set with greater confidence as it directly reflects our own target population. Optimization of meropenem dosing based on pharmacodynamic profile and Monte Carlo simulation lays the groundwork for clinical efficacy studies in the future. Based on results from previous studies, optimization of meropenem dosing has the potential to produce better patient outcomes, reduce drug utilization and cost and reduce rates of resistance. These can be examined in future clinical studies.

Conditions

Cystic Fibrosis Pulmonary Exacerbation

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Blinding Strategy: NONE

Study Groups

Extended Meropenem Infusion

Meropenem Infusion over 3 hours

Group Type: EXPERIMENTAL

Meropenem Infusion

Intervention Type: DRUG

Meropenem 2g infused intravenously over 30 mins (bolus infusion) Meropenem 2g infused intravenously over 3 hours (extended infusion)

Bolus Meropenem Infusion

Meropenem infusion over 30 minutes

Group Type: EXPERIMENTAL

Meropenem Infusion

Intervention Type: DRUG

Meropenem 2g infused intravenously over 30 mins (bolus infusion) Meropenem 2g infused intravenously over 3 hours (extended infusion)

Interventions

Meropenem Infusion

Meropenem 2g infused intravenously over 30 mins (bolus infusion) Meropenem 2g infused intravenously over 3 hours (extended infusion)

Intervention Type: DRUG

Other Intervention Names

Meropenem or Merrem(R)

Eligibility Criteria

Inclusion Criteria

• ≥18 years old,
• currently experiencing new or exacerbation of active pulmonary infection as evidenced by increased coughing, sputum production, wheezing, white blood count and/or fever,
• requires meropenem for treatment,
• recent sputum culture positive for P. aeruginosa and/or B. cepacia at a prior visit,
• be able to provide written informed consent.

Exclusion Criteria

• hypersensitivity and/or intolerance to meropenem,
• history of seizures,
• current use of valproic acid,
• significant psychiatric illness,
• contraindication to insertion of a venous catheter,
• worsening of clinical status requiring admission to intensive care unit (ICU),
• creatinine clearance ≤50 ml/min,
• significant cystic fibrosis-related liver dysfunction characterized by portal hypertension and cirrhosis

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sunnybrook Health Sciences Centre

OTHER

Sponsor Role: collaborator

University of Toronto

OTHER

Sponsor Role: collaborator

Unity Health Toronto

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Daniel Cortes

Role: PRINCIPAL_INVESTIGATOR

Unity Health Toronto

Locations

St. Michael's Hospital

Toronto, Ontario, Canada

Countries

Canada

Other Identifiers

REB#08-316

Identifier Type: -

Identifier Source: org_study_id